Philippines Business News
Local business and financial news scraped every 4 hours from BusinessWorld, PhilStar, Manila Times, Rappler, and more.
4650 articles from Manila Times Business
Societe Generale: shares and voting rights as of 23 September 2026
Regulated information Number of shares composing current share capital and total number of voting rights as of 23 September 2026 Paris, 1 October 2026 Information about the total number of voting rights and shares pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulations. DateNumber of shares composing current share capitalTotal number of voting rights 23 September 2026739,264,232 Gross: 821,187,225Press contacts: Jean-Baptiste Froville _ +33
Read more →NMDP Gala Highlights Financial Challenges Facing Patients in Need of Blood Stem Cell Transplants
Patient financial assistance requests are up 34% as NMDP and its supporters work to help more families overcome barriers to treatment NMDP Minneapolis Gala- Honorary Chairs NMDP Minneapolis Gala Honorary Chairs, Greg and Wendy Hirons NMDP Minneapolis Gala; Chief Philanthropy Officer NMDP's Chief Philanthropy Officer Jess Kowal speaks to the audience at NMDP's 19th annual fundraising gala in Minneapolis, MN. NMDP Gala: 14-year old Brady Wanous meets the woman who saved his life, Cara Serbentes. T
Read more →Participation notification by Citigroup Inc.
Press release Regulated information Brussels, October 1, 2026, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notification indicating that it crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalSeptember 24, 20260.43%2.66%3.09% The notification, dated Se
Read more →ARGAN: RENTAL INCOME UP +5% OVER THE FIRST NINE MONTHS OF 2026
Quarterly financial information - Neuilly-sur-Seine, Thursday, October 1, 2026 - 5.45 pm Rental income up +5% over the first nine months of 2026 Rental income (IFRS) as at September 30, 2026 (unaudited figures) € million20262025Trends 1st quarter (Jan. - March)54.452.9+ 3%2nd quarter (April - June)55.352.9+ 5%3rd quarter (July - Sept.)56.552.9+ 7%Total first nine months166.2158.7+ 5%€166.2 million in rental income over the first nine months of 2026 Over the first nine months of 2026, ARGAN, the
Read more →Clariant acknowledges the closing of the Stahl transaction between Wendel SE and Henkel
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Muttenz, 01 October 2026 Clariant, a sustainability-focused specialty chemical company, today took note of the successful closing between Stahl Group’s majority and controlling owner Wendel SE and Henkel. The existing shareholder agreement included a contractual obligation for Clariant as minority shareholder to participate in the transaction following the notification from Wendel SE. Clariant held a minority stake of 14.6 % in Stahl Group. Based on tod
Read more →Transgene to Participate in Investor Access
Strasbourg, France, October 1, 2026, 5:45 pm CET - Transgene (Euronext Paris: TNG), a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence together with a portfolio of virus-based candidates, today announced that its management team will meet institutional investors during the upcoming edition of Investor Access Event (by Investor Access), on October 6, 2026, in Paris. Organized by Investor Access, these events
Read more →Coface SA: Disclosure of total number of voting rights and number of shares in the capital as at September 30, 2026
COFACE SA: Disclosure of total number of voting rights and number of shares in the capital as at September 30, 2026 Paris, October 1st, 2026 - 5.45 p.m. Total Number of Shares Capital Theoretical Number of Voting Rights1Number of Real Voting Rights2 150,179,792150,179,792149,512,977 (1) including own shares (2) excluding own shares Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by Wiztrust. You can check the authenticity on the website
Read more →Marimekko Corporation: Repurchase of own shares during week 40/2026
Marimekko Corporation, Stock Exchange Release, 1 October 2026 at 6.45 p.m. EEST Marimekko Corporation: Repurchase of own shares during week 40/2026 Marimekko Corporation has acquired its own shares during week 40 in the Helsinki Stock Exchange as follows: Trade dateSharesAverage price / shareTotal cost28.9.202613,8069.5943132,458.9129.9.202612,3759.5976118,770.3030.9.202611,3339.6112108,923.731.10.20261,9009.448117,951.39Total amount, week 40 39,4149.5931378,104.33 Marimekko Corporation now hold
Read more →Nexity: total number of voting rights and shares composing the share capital as of 30 Septembre 2026
NEXITY Société anonyme au capital de 280 648 620 euros Siège Social : 67 rue Arago 93400 Saint-Ouen-sur-Seine 444 346 795 RCS Bobigny Monthly disclosure of the total number of voting rights and shares composing the share capital in accordance with Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Information cut-off dateTotal number of shares Net total number of voting rights 30 September 202656,129,724Total gross56,129
Read more →WENDEL: Wendel finalized the sale of Stahl to Henkel
PRESS RELEASE – OCTOBER 1, 2026 Wendel finalized the sale of Stahl to Henkel Net proceeds of €1.14 billion for Wendel, representing an annualized IRR of over 15% since 2006 Wendel (Euronext: MF.FP) announces it finalized the sale of its stake in Stahl (excluding Muno) for an enterprise value of €2.1 billion to Henkel, following receipt of all required regulatory approvals. The transaction has generated total net proceeds (after debt and transaction costs) of c.€1.14 billion for Wendel. This corr
Read more →Declaration of number of voting rights
Declaration of number of voting rights Information relating to the total number of voting rights and shares as required by L.233-8 II of the code of commerce and article 223-16 of the general rules of the French market authority (AMF). DateNumber of sharesTotal number of voting rights 09/30/2026 262,769,869Theoretical number of voting rights1:375,182,213 1 The theoretical voting rights include all voting rights, including double voting rights. Attachment PR voting rights_30 Sept
Read more →Bouygues: Monthly disclosure of the total number of shares and voting rights
Monthly disclosure of the total number of shares and voting rights Paris, 01/10/26 Article 223-16 of the AMF General Regulation DateSharesVoting rightsTheoritical (1)Exercisable (2)30 Septembre 2026388,438,129499,578,572496,449,201 (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) For information purposes only, this num
Read more →Momentum has been named the Sponsorship Marketing Association’s Agency of the Year
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Momentum has been named Agency of the Year by the Sponsorship Marketing Association (SMA), marking a first for the agency. The SMA cited Momentum for delivering its biggest year yet, executing disruptive activations in 2025 at the FIFA Club World Cup, Super Bowl and F1 for brands including Anheuser-Busch, Coca-Cola, GEICO, Verizon and Walmart. "We are proud to be recognized as the SMA’s Agency of the Year,” said Momentum Global President & CMO Kevin Mc
Read more →Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will ad
Read more →FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation ("Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TRE-515 in combination with KRAS inhibitors for the treatment of G12C mutation-positive non-small cell lung cancer (NSCLC) previously treated with an anti-PD-(L)1 antibody and platinum-based chemothe
Read more →Rapper Rick Ross charged with battery after domestic violence accusation
MIAMI BEACH, Florida — Rapper Rick Ross was arrested in Miami Beach early Thursday and charged with battery related to a domestic violence accusation, authorities said. Ross, whose legal name is William Roberts II, faces a felony charge of battery by strangulation, as well as a misdemeanor battery charge, according to online court records. An attorney for Ross, 50, said in a statement that Ross is being wrongfully accused by an ex-girlfriend whose true motivations are unclear. “The e
Read more →Candelaria wins silver in Asian Games poomsae
MANILA, Philippines — Teenager Juliana Mykhail Candelaria finished with a silver medal in women's individual poomsae on Thursday afternoon in the 20th Asian Games at the Toyohashi Gymnasium in Aichi, Japan. The 18-year-old Candelaria showed poise and grace in her routine, scoring 9.1300 points for a silver medal. South Korea's Haeun Jung scored 9.310 for the gold. Thitaree Kaewolanwasu completed the podium with 9.040 points.
Read more →Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Company announcement - No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a po
Read more →Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Ingelheim, Germany Illustrative photo In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1Detailed results from the Phase III trial indicate survodutide improves key markers of cardiometabolic health, including a reduction of up to 1.21% in Hb
Read more →DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform. The platform brings together antibody design, structure prediction and validation too
Read more →Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Numab Therapeutics ("Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, today announced the appointment of Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. Numab has pioneered a differentiated approach to multispecific antibody engi
Read more →Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in fat massData provide first human proof-of-mechanism and support Atrogi’s planned Phase 2 trial expected to initiate in 2027 STOCKHOLM, Sweden, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Atrogi AB, a clinical-stage biotech company pioneering novel GPCR pa
Read more →CROSSVOLUTION Is Coming: OMODA X to Make Its Global Debut on October 20, Opening Up New Possibilities for Crossover
WUHU, China, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The appeal of Crossover has always been its limitless potential. There are no fixed answers and no predetermined boundaries. It brings together qualities once thought to belong to different worlds, allowing familiar forms to take on an entirely new edge. Crossover | Always Opening Up What Comes Next As a global expert in the Crossover , OMODA has never stopped reimagining what crossover means. From the OMODA 5, which emphasizes sportiness and a futu
Read more →